Standout Papers

Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinb... 2011 2026 2016 2021 502
  1. Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986 (2011)
    Maria De Santis, Joaquim Bellmunt et al. Journal of Clinical Oncology

Immediate Impact

2 by Nobel laureates 19 from Science/Nature 66 standout
Sub-graph 1 of 19

Citing Papers

Natural killer cell therapies
2024 StandoutNature
Narrow Bandgap Schottky Heterojunction Sonosensitizer with High Electron–Hole Separation Boosted Sonodynamic Therapy in Bladder Cancer
2024 Standout
2 intermediate papers

Works of Julie Lorent being referenced

IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells
2016
Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
2011 Standout

Author Peers

Author Last Decade Papers Cites
Julie Lorent 429 232 95 481 15 937
Jinxiong Wei 260 407 74 313 17 806
Rafael E. Curiel 333 247 107 200 22 838
Michelle L. Badura 567 375 85 172 12 1.1k
C Cordón-Cardó 201 416 82 243 19 882
Ilvars Silins 291 331 127 232 22 947
V E Reuter 321 492 192 511 17 1.0k
Wendell C. Speers 245 600 110 131 22 1.1k
Tiangui Huang 224 321 110 88 19 777
Rania Dagher 160 310 37 389 17 924
Brian P. Mullaney 463 347 115 158 25 1.1k

All Works

Loading papers...

Rankless by CCL
2026